

Haematologica  
HAEMATOL/2017/177600  
Version 3

Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions  
in splenomegaly in patients with MPNs

Gabriela S. Hobbs, Amritha Varshini Hanasoge Somasundara, Maria  
Kleppe, Rivka Litvin, Maria Arcila, Jihae Ahn, Anna Sophia Mckenney,  
Kristina Knapp, Ryan Ptashkin, Howard Weinstein, Murk-Hein  
Heinemann, Jasmine Francis, Suzanne Chanel, Ellin Berman, Michael  
Mauro, Martin S. Tallman, Mark L. Heaney, Ross L. Levine, and Raajit  
K. Rampal

Disclosures: This work was supported by funding from Novartis Pharmaceuticals; Cancer  
Center Support Grant/Core Grant to Memorial Sloan Kettering Cancer Center (P30  
CA008748); NCI 1K08CA188529-01 (R.K.R); KK12CA087723-14 (G.S.H); NCI  
R01CA173636 (R.L.L); K99 HL122503-01A1 (M.K.); NIH National Institute of General  
Medical Sciences Grant T32 GM007739 and NCI F30CA18349 (A.S.M).

Contributions: Contributions: R.K.R., G.S.H., and M.L.H designed the study. R.K.R.,  
G.S.H., M.T., E.B., M.M., M.L.H, J.F., H.W., S.C. and J.F. carried out the clinical  
investigations. R.L. and K.K. provided regulatory support and guidance for the study.  
Correlative biomarker studies were designed by R.K.R. and R.L.L., and carried out by  
R.K.R., M.K., A.V.H.S., A.S.M., J.A., M.A., and R.P. Data was analyzed by R.K.R. and  
G.S.H. Manuscript was written by R.K.R. and G.S.H